3 Stocks Advancing The Health Care Sector

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 4 points (0.0%) at 17,970 as of Thursday, June 25, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,139 issues advancing vs. 1,826 declining with 188 unchanged.

The Health Care sector currently sits down 0.2% versus the S&P 500, which is up 0.1%. Top gainers within the sector include Tenet Healthcare ( THC), up 14.0%, HCA Holdings ( HCA), up 8.8%, Universal Health Services ( UHS), up 7.9%, Envision Healthcare Holdings ( EVHC), up 5.1% and UnitedHealth Group ( UNH), up 2.8%. On the negative front, top decliners within the sector include Waters ( WAT), down 3.9%, Biomarin Pharmaceutical ( BMRN), down 1.5% and Pfizer ( PFE), down 0.8%.

TheStreet would like to highlight 3 stocks pushing the sector higher today:

3. Express Scripts ( ESRX) is one of the companies pushing the Health Care sector higher today. As of noon trading, Express Scripts is up $0.84 (0.9%) to $91.46 on average volume. Thus far, 1.8 million shares of Express Scripts exchanged hands as compared to its average daily volume of 4.3 million shares. The stock has ranged in price between $90.33-$91.90 after having opened the day at $90.98 as compared to the previous trading day's close of $90.62.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company operates through two segments, PBM and Other Business Operations. Express Scripts has a market cap of $66.2 billion and is part of the health services industry. Shares are up 7.3% year-to-date as of the close of trading on Wednesday. Currently there are 12 analysts who rate Express Scripts a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Express Scripts as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full Express Scripts Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading, Eli Lilly and ( LLY) is up $3.36 (4.1%) to $85.62 on heavy volume. Thus far, 5.8 million shares of Eli Lilly and exchanged hands as compared to its average daily volume of 4.8 million shares. The stock has ranged in price between $84.08-$86.90 after having opened the day at $84.14 as compared to the previous trading day's close of $82.26.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health products. Eli Lilly and has a market cap of $91.7 billion and is part of the drugs industry. Shares are up 19.8% year-to-date as of the close of trading on Wednesday. Currently there are 7 analysts who rate Eli Lilly and a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Eli Lilly and as a buy. The company's strengths can be seen in multiple areas, such as its expanding profit margins, solid stock price performance and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Eli Lilly and Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading, Regeneron Pharmaceuticals ( REGN) is up $6.44 (1.2%) to $523.03 on light volume. Thus far, 228,178 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 780,900 shares. The stock has ranged in price between $516.60-$525.95 after having opened the day at $517.97 as compared to the previous trading day's close of $516.59.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Regeneron Pharmaceuticals has a market cap of $52.8 billion and is part of the drugs industry. Shares are up 27.0% year-to-date as of the close of trading on Wednesday. Currently there are 12 analysts who rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, growth in earnings per share and increase in net income. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Regeneron Pharmaceuticals Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

If you liked this article you might like

Drug Supply Chain Stocks Dip After White House Recommendations on Drug Pricing

Drug Supply Chain Stocks Dip After White House Recommendations on Drug Pricing

CVS Tumbles on Amazon News but Analysts Say It Could Be a Positive

CVS Tumbles on Amazon News but Analysts Say It Could Be a Positive

Cramer: How to Play the Volatility in UnitedHealth and Others

Cramer: How to Play the Volatility in UnitedHealth and Others

Changes to Federal Tax Law Just What the Doctor Ordered for Healthcare Firms

Changes to Federal Tax Law Just What the Doctor Ordered for Healthcare Firms

Here's Who Might Be on Amazon's M&A Shopping List in 2018

Here's Who Might Be on Amazon's M&A Shopping List in 2018